Modulation of colorectal tumor behavior via lncRNA TP53TG1-lipidic nanosystem
Masoumi, Farimah (Islamic Azad University)
Saraiva, Sofia M. (Centro de Investigación Biomédica en Red de Cáncer)
Bouzo, Belén L. (Instituto de Investigación Sanitaria de Santiago (IDIS))
López-López, Rafael (Instituto de Investigación Sanitaria de Santiago (IDIS))
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Diaz-Lagares, Angel (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
de la Fuente, María (Centro de Investigación Biomédica en Red de Cáncer)

Date:	2021
Abstract:	Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53-mediated DNA damage and the intracellular localization of the oncogenic YBX1 protein. However, to translate this finding into the clinic as a gene therapy, it is important to develop effective carriers able to deliver exogenous lncRNAs to the targeted cancer cells. Here, we propose the use of biocompatible sphingomyelin nanosystems comprising DOTAP (DSNs) to carry and deliver a plasmid vector encoding for TP53TG1 (pc(TP53TG1)-DSNs) to a colorectal cancer cell line (HCT-116). DSNs presented a high association capacity and convenient physicochemical properties. In addition, pc(TP53TG1)-DSNs showed anti-tumor activities in vitro, specifically a decrease in the proliferation rate, a diminished colony-forming capacity, and hampered migration and invasiveness of the treated cancer cells. Consequently, the proposed strategy displays a high potential as a therapeutic approach for colorectal cancer.
Grants:	Instituto de Salud Carlos III AC18/00107 Instituto de Salud Carlos III DTS18-00133 Instituto de Salud Carlos III PI18/00176 Instituto de Salud Carlos III PI18/00307
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Pharmaceutics, Vol. 13 Núm. 9 (september 2021) , art. 1507, ISSN 1999-4923

DOI: 10.3390/pharmaceutics13091507
PMID: 34575588

16 p, 1.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles